异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关

异动解读12-19

歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。

根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。

一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期前景的疑虑,因此引发了投资者的担忧情绪,从而导致公司股价今日大幅下挫。不过,临床前研究数据并不代表最终疗效,公司尚需进一步开展临床研究,ASC47的前景有待观察。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1187949470?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-19 09:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187949470","market":"us","top_or_hot":-1,"title":"异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关","media":"异动解读","content":"<p>歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。</p>\n\n<p>根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。</p>\n\n<p>一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期前景的疑虑,因此引发了投资者的担忧情绪,从而导致公司股价今日大幅下挫。不过,临床前研究数据并不代表最终疗效,公司尚需进一步开展临床研究,ASC47的前景有待观察。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 歌礼制药-B(01672)盘中大跌5.28%,与候选药物临床前减重效果疲软有关\n</h2>\n\n<h4 class=\"meta\">\n\n2024-12-19 09:34 北京时间&nbsp;&nbsp;&nbsp;<strong>异动解读</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。\n根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。\n一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1187949470","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187949470","pubTimestamp":1734572080,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。\n\n根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。\n\n一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期前景的疑虑,因此引发了投资者的担忧情绪,从而导致公司股价今日大幅下挫。不过,临床前研究数据并不代表最终疗效,公司尚需进一步开展临床研究,ASC47的前景有待观察。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"Interpretation of the change Ascletis Pharmaceuticals-B (01672) fell 5.28% during the session, which was related to the weak preclinical weight loss effect of drug candidates","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"歌礼制药-B(01672)今日盘中出现大跌行情,截至上午收盘,累计下跌5.28%,引发了市场广泛关注。\n根据公司公告,歌礼制药与治疗肥胖症的减重不减肌候选药物ASC47有关。公告显示,ASC47与司美格鲁肽联合用药在临床前模型中虽显示出优于司美格鲁肽单药的减重效果,但整体效果依然疲软,远未达到市场预期。\n一些分析人士指出,作为公司主要在研管线之一,ASC47的疗效不达预期可能加大了市场对公司长期前景的疑虑,因此引发了投资者的担忧情绪,从而导致公司股价今日大幅下挫。不过,临床前研究数据并不代表最终疗效,公司尚需进一步开展临床研究,ASC47的前景有待观察。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187949470"}